Glucagon ELISA

Kit Calculator

Estimate required kits based on your number of samples.

Samples

Article no.

Sample setup

Add the number of samples you plan to run. Please ensure that each sample has sufficient volume to meet the kit’s per-well requirement.

Controls

Add a corresponding Mercodia control kit. Note: If controls are selected, more than one control kit may be needed depending on the number of assay kits used and the time between runs

The results show the estimated number of assay kits required based on your input and the assay’s DfU. Actual kit usage may vary depending on workflow and run frequency.

Minimal Number of Kits Required:

(10-1271-01)

Kit format: 1 x 96 wells

Measurement range: 1.5 – 130 pmol/L (5 – 453 pg/mL)

No cross-reactivity to glicentin, proglucagon 1-16, and glucagon 3-29

CE/IVD labeled on selected markets

No purification of samples

Controls available: 10-1286-01

TALK TO A PERSON

Description

The Mercodia Glucagon ELISA is a CE/IVD-labelled, highly specific and sensitive immunoassay for measuring glucagon in plasma and serum.

The highly specific monoclonal antibodies used in this assay enable accurate determination of glucagon without significant cross-reactivity to other circulating pro-glucagon-derived peptides, e.g. glicentin.

As of October 1st, 2020, the assay protocol of Mercodia Glucagon ELISA 10-1271-01 is updated to make the sequential protocol default, abolishing cross-reactivity to glicentin. To run the old, simultaneous protocol, please refer to Technical Note TN34-161.

Mercodia Glucagon Control – Low, Medium, High (10-1286-01) is a three-level control for Mercodia Glucagon ELISA.

Test characteristics

Species

Human

Sample volume

25 µL

Sample types

Serum, EDTA plasma and cell culture medium

Assay range

1.5-130 pmol/L (5.95-453pg/mL)

Detection limit

≤1.0 pmol/L

Incubation

18-22 h (overnight) + 1 h + 30 min

Detection method

Absorbance

specificity

The following cross-reactions have been tested:

Glicentin

Not detected

Oxyntomodulin

4.0 %

Proglucagon (1-61)

Not detected

Glucagon (3-29)

Not detected

directions for use Certificate of Analysis

directions for use

LOT. NO.	DOCUMENT
36861	DfU - 10-1271-01 v. 14.0
36743	DfU - 10-1271-01 v. 14.0
36551	DfU - 10-1271-01 v. 14.0
36311	DfU - 10-1271-01 v. 13.0
36136	DfU - 10-1271-01 v. 13.0
36077	DfU - 10-1271-01 v. 13.0
35843	DfU - 10-1271-01 v. 13.0
35567	DfU - 10-1271-01 v. 13.0
35430	DfU - 10-1271-01 v. 12.0
35184	DfU - 10-1271-01 v. 12.0
33986	DfU - 10-1271-01 v. 12.0
33439	DfU - 10-1271-01 v. 12.0
33191	DfU - 10-1271-01 v. 12.0

Certificate of Analysis

LOT. NO.	DOCUMENT
36861	CoA - 10-1271-01
36743	CoA - 10-1271-01
36551	CoA - 10-1271-01
36311	CoA -10-1271-01
36136	CoA - 10-1271-01
36077	CoA - 10-1271-01
35843	CoA - 10-1271-01
35567	CoA - 10-1271-01
35430	CoA - 10-1271-01
35184	CoA - 10-1271-01
33986	CoA - 10-1271-01
33439	CoA - 10-1271-01
33191	CoA - 10-1271-01

For other languages and previous versions: Technical Library

SAFETY DATA SHEET

technical notes

For technical notes specific to Mercodia Glucagon ELISA see:
TN34-0146 Sample collection and handling with Mercodia Glucagon ELISAs
TN34-0161 Simultaneous protocol for Mercodia Glucagon ELISA (10-1271-01)

For other technical notes see our Technical Library

references

Kahn, S.E. et al. (2021). Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. Diabetes Care, Jun; dc210460. Read more >

Zhu, X. et al. (2021). SGLT2i increased the plasma fasting glucagon level in patients with diabetes: A meta-analysis. European Journal of Pharmacology, 903, 174145 Read more >

Bevacqua, R. J. et al. (2021). CRISPR-based genome editing in primary human pancreatic islet cells. Nature Communications, 12(1), 2397. Read more >

Alexiadou, K. et al. (2020). Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study. BMJ open diabetes research & care, 8(1), e001076. Read more >

Stern, J. H. et al. (2019) Obesity dysregulates fasting-induced changes in glucagon secretion. J. Endocrinol. 243(2), 149–1606. Read more >

Roberts GP et al (2018) Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery. Surg Obes Relat Dis May;14(5):562-5682. Read more >

Gar, C. et al. (2018) Patterns of plasma glucagon dynamics do not match metabolic phenotypes in young women. J. Clin. Endocrinol. Metab. 103, 972–982. Read more >

Raffort, J. et al. (2017) Fasting Circulating Glicentin Increases After Bariatric Surgery. Obes Surg 27:1581–1588. Read more >

Miyachi, A. et al. (2017) Accurate analytical method for human plasma glucagon levels using liquid chromatography-high resolution mass spectrometry: comparison with commercially available immunoassays. Anal. Bioanal. Chem. 409, 5911–5918. Read more >

Wewer Albrechtsen, N. J. et al. (2014) Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 57, 1919–1926. Read more >